en
/
sv
About Elicera
Elicera in brief
Board
Team
Advisors
Elicera's history
Immuno-oncology
What is immuno-oncology?
CAR T-cell therapy
Oncolytic virus
Technology
CAR T-cell therapy
Challenges
Mode-of-action
Scientific publications
Pipeline
Pipeline
ELC-301
ELC-401
ELC-201
ELC-100
Clinical trials
Patent portfolio
Investors
Press Releases
Corporate Governance
the Share
Financial Reports
Financial Calendar
Events
Share issues
Analyst Coverage
News
News
Press Releases
Events
Contact
en
/
sv
News
2026
2025
2024
2023
2022
2021
2020
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Jan 14, 2022
2022
Press Release Regulatory
The Nomination Committee for Elicera Therapeutics proposes re-election of Board
Regulatory Press Release
Read more
Jan 5, 2022
2022
Press Release Non-regulatory
Elicera Therapeutics strengthens IP protection for ELC-100 through acquisition of patent from Immunicum
Non-regulatory Press Release
Read more
Jan 5, 2022
2022
News
Nordic Life Science News writes about Elicera's patent acquisition from Immunicum
News
Read more
Dec 15, 2021
2021
Press Release Non-regulatory
Elicera Therapeutics enters into agreement with Baylor College of Medicine for contract manufacturing of next generation oncolytic virus, ELC-201
Non-regulatory Press Release
Read more
Nov 18, 2021
2021
Press Release Regulatory
Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2021
Regulatory Press Release
Read more
Nov 9, 2021
2021
Press Release Non-regulatory
Elicera Therapeutics enters agreement with BioNTech for contract manufacturing of viral vectors for CAR T-cell therapy
Non-regulatory Press Release
Read more
Nov 4, 2021
2021
Press Release Regulatory
Nomination Committee for Elicera Therapeutics appointed
Regulatory Press Release
Read more
Oct 22, 2021
2021
Press Release Non-regulatory
Elicera Therapeutics appoints professor Gunilla Enblad, Key Opinion Leader within the fields of CAR T-cells and B-cell lymphoma, as scientific advisor
Non-regulatory Press Release
Read more
Oct 20, 2021
2021
Press Release Regulatory
Elicera Therapeutics presents preclinical proof-of-concept data for its iTANK-platform at the European Society of Cell & Gene Therapy Congress
Regulatory Press Release
Read more
Oct 20, 2021
2021
News
Nordic Life Science News
News
Read more
Oct 5, 2021
2021
Press Release Non-regulatory
Elicera Therapeutics announces participation in several industry and investor meetings in October and November
Non-regulatory Press Release
Read more
Sep 13, 2021
2021
Press Release Non-regulatory
Elicera Therapeutics will present the iTANK platform orally at ESGCT Collaborative Virtual Congress and PEGS Europe
Non-regulatory Press Release
Read more
Aug 20, 2021
2021
Press Release Non-regulatory
Interim Report Elicera Therapeutics AB January – June 2021
Non-regulatory Press Release
Read more
Jul 5, 2021
2021
Press Release Non-regulatory
Elicera Therapeutics’ warrants (TO1) are listed on First North Growth Market
Non-regulatory Press Release
Read more
Jul 5, 2021
2021
Press Release Non-regulatory
Elicera Therapeutics' board and management buy shares
Non-regulatory Press Release
Read more
Jun 24, 2021
2021
Press Release Non-regulatory
Elicera Therapeutics receives ATMP-classification from EMA for oncolytic virus
Non-regulatory Press Release
Read more
Jun 10, 2021
2021
Press Release Non-regulatory
Elicera Therapeutics has been approved for listing on Nasdaq First North Growth Market
Non-regulatory Press Release
Read more
Jun 9, 2021
2021
Press Release Non-regulatory
Elicera Therapeutics' new issue heavily oversubscribed
Non-regulatory Press Release
Read more
Jun 4, 2021
2021
Press Release Non-regulatory
Elicera Therapeutics’ last day to subscribe ahead of the listing at Nasdaq First North Growth Market
Non-regulatory Press Release
Read more
Jun 3, 2021
2021
News
CEO-interview by Nyhetsbyrån Direkt
News
Read more
Previous
+ Load more
6 / 8
Sign up for Press Releases
By filling out the form you are approving that Elicera stores your information. Read more about our integrity policy
here
.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our
Integrity policy
.
Deny
Accept